WO2022143515A1 - Variant de polypeptide glp-1 humain et son application - Google Patents

Variant de polypeptide glp-1 humain et son application Download PDF

Info

Publication number
WO2022143515A1
WO2022143515A1 PCT/CN2021/141606 CN2021141606W WO2022143515A1 WO 2022143515 A1 WO2022143515 A1 WO 2022143515A1 CN 2021141606 W CN2021141606 W CN 2021141606W WO 2022143515 A1 WO2022143515 A1 WO 2022143515A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
human glp
polypeptide variant
glp
Prior art date
Application number
PCT/CN2021/141606
Other languages
English (en)
Chinese (zh)
Inventor
徐霆
金宇灏
汪皛皛
王媲琳
李倩
Original Assignee
苏州康宁杰瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州康宁杰瑞生物科技有限公司 filed Critical 苏州康宁杰瑞生物科技有限公司
Publication of WO2022143515A1 publication Critical patent/WO2022143515A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un variante de polypeptide GLP-1 humain. Une protéine de fusion ou un immunoconjugué construit à l'aide du variant de polypeptide GLP-1 humain peut être utilisée pour prévenir et/ou traiter des maladies ou des troubles métaboliques liés à GLP-1.
PCT/CN2021/141606 2020-12-29 2021-12-27 Variant de polypeptide glp-1 humain et son application WO2022143515A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011601861.7A CN114685643A (zh) 2020-12-29 2020-12-29 一种人glp-1多肽变体及其应用
CN202011601861.7 2020-12-29

Publications (1)

Publication Number Publication Date
WO2022143515A1 true WO2022143515A1 (fr) 2022-07-07

Family

ID=82131759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/141606 WO2022143515A1 (fr) 2020-12-29 2021-12-27 Variant de polypeptide glp-1 humain et son application

Country Status (2)

Country Link
CN (1) CN114685643A (fr)
WO (1) WO2022143515A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208099A (zh) * 2004-07-21 2008-06-25 Ambrx公司 利用非天然编码氨基酸的生物合成多肽
CN102093475A (zh) * 2009-12-11 2011-06-15 吴晓琰 胰高血糖素样肽-1的类似物
CN102363633A (zh) * 2011-11-16 2012-02-29 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
US20120129768A1 (en) * 2009-07-30 2012-05-24 Jiangsu Hansoh pharmaceutical Group Co. Ltd Glp-1 analogues and their pharmaceutical salts and uses
WO2018115401A1 (fr) * 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du composé fgf21/agoniste du glp-1r ayant un rapport d'activité optimisé
CN108699120A (zh) * 2015-11-16 2018-10-23 Ubi蛋白公司 用于延长蛋白质半衰期的方法
CN110865129A (zh) * 2018-08-27 2020-03-06 齐鲁制药有限公司 一种度拉鲁肽中多种修饰水平的检测方法
US20200384119A1 (en) * 2017-06-21 2020-12-10 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208099A (zh) * 2004-07-21 2008-06-25 Ambrx公司 利用非天然编码氨基酸的生物合成多肽
US20120129768A1 (en) * 2009-07-30 2012-05-24 Jiangsu Hansoh pharmaceutical Group Co. Ltd Glp-1 analogues and their pharmaceutical salts and uses
CN102093475A (zh) * 2009-12-11 2011-06-15 吴晓琰 胰高血糖素样肽-1的类似物
CN102363633A (zh) * 2011-11-16 2012-02-29 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
CN108699120A (zh) * 2015-11-16 2018-10-23 Ubi蛋白公司 用于延长蛋白质半衰期的方法
WO2018115401A1 (fr) * 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du composé fgf21/agoniste du glp-1r ayant un rapport d'activité optimisé
US20200384119A1 (en) * 2017-06-21 2020-12-10 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
CN110865129A (zh) * 2018-08-27 2020-03-06 齐鲁制药有限公司 一种度拉鲁肽中多种修饰水平的检测方法

Also Published As

Publication number Publication date
CN114685643A (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
US10538586B2 (en) Compositions and methods for treating fatty tissue buildup
CN109836503B (zh) 一种治疗代谢疾病的多重活性蛋白
JP2013506628A (ja) 延長された半減期を有する薬物融合物及びコンジュゲート
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
KR20170049319A (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN113603794A (zh) 用于调节血糖和脂质的增效型双功能蛋白
KR20180052545A (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
US20230020626A1 (en) Compositions and methods for treating obesity and hyperphagia
WO2022143515A1 (fr) Variant de polypeptide glp-1 humain et son application
WO2022143516A1 (fr) Variant de polypeptide glp-1 humain et son utilisation
WO2018102654A1 (fr) Compositions et méthodes de traitement de l'obésité et de l'hyperphagie
WO2023280133A1 (fr) Protéine de fusion et son application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21914251

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21914251

Country of ref document: EP

Kind code of ref document: A1